戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 inhibited (IC50 = 35 microM) by zaprinast, a PDE5 inhibitor.
2 ter sun exposure among patients exposed to a PDE5 inhibitor.
3 postinil, inorganic nitrate (NO donor), or a PDE5 inhibitor.
4 s have been prepared as potent and selective PDE5 inhibitors.
5 discovered as extremely potent and selective PDE5 inhibitors.
6 ibitor, celecoxib, was used to develop novel PDE5 inhibitors.
7 ts of long-term treatments with low doses of PDE5 inhibitors.
8  a novel series of aminopyridopyrazinones as PDE5 inhibitors.
9 hypertrophic and cardioprotective effects of PDE5 inhibitors.
10 y sildenafil, a popular phosphodiesterase 5 (PDE5) inhibitor.
11 nduction are blocked by phosphodiesterase 5 (PDE5) inhibitors.
12 ent animal and human data support the use of PDE5 inhibitor and the generation of early erections aft
13 imal and human studies imply that the use of PDE5 inhibitor and the generation of erections early aft
14                                Ever use of a PDE5 inhibitor and time-updated cumulative number of PDE
15                         All men initiating a PDE5 inhibitor and with no prior cancer diagnosis were i
16                  Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP al
17                               Combination of PDE5 inhibitors and alpha1-adrenergic blockers may have
18                    Combination therapy using PDE5 inhibitors and alpha1-adrenergic blockers resulted
19 This study found that combination therapy of PDE5 inhibitors and antioxidants was associated with imp
20                               Treatment with PDE5 inhibitors and chemotherapy drugs promoted autophag
21                               Treatment with PDE5 inhibitors and daily tadalafil, shockwaves, or a va
22  between the coprescription of nitrates with PDE5 inhibitors and the risk for either composite outcom
23 denafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor and potent vasodilator.
24                         Phosphodiesterase-5 (PDE5) inhibitors and other agents that modulate intracel
25 erized bovine hemoglobin (HBOC), sildenafil (PDE5 inhibitor), and lactated Ringer's solution (control
26 and is additive with prostacyclin analogues, PDE5 inhibitor, and NO.
27                                      Because PDE5 inhibitors are currently used as therapeutic agents
28               Recent studies have shown that PDE5 inhibitors are potent acute pulmonary vasodilators
29                   Given that side effects of PDE5 inhibitors are widely known and do not preclude the
30                         Phosphodiesterase-5 (PDE5) inhibitors are suggested to have anti-tumor effect
31 ates, and may ultimately provide a basis for PDE5 inhibitors as a treatment for pulmonary hypertensio
32 dings demonstrate a potentially novel use of PDE5 inhibitors as adjuncts to tumor-specific immune the
33                         We report the use of PDE5 inhibitors as modulators of the antitumor immune re
34 , 435 men (11%) had filled prescriptions for PDE5 inhibitors, as did 1713 men of 20,325 controls (8%)
35                                          The PDE5 inhibitors augment the antithrombotic effects of ni
36                                          The PDE5 inhibitors augment the blood pressure (BP)-lowering
37         Our results were not consistent with PDE5 inhibitors being causally associated with melanoma
38                        It is recognized that PDE5 inhibitors can have cardioprotective effects in oth
39 fil citrate (Viagra), a phosphodiesterase 5 (PDE5) inhibitor, can be used to ameliorate the age-relat
40           Sildenafil, a phosphodiesterase-5 (PDE5) inhibitor causing accumulation of cGMP, is frequen
41 ion recapitulated the combination effects of PDE5 inhibitor drugs with chemotherapy drugs.
42                                              PDE5 inhibitors (eg, sildenafil) are licensed for PH, bu
43                                              PDE5 inhibitors enhanced and prolonged the induction of
44 rently filled prescriptions for nitrates and PDE5 inhibitors equaled concomitant use.
45 research, highlight the potential utility of PDE5 inhibitors for ameliorating emotion recognition def
46           This article focuses on the use of PDE5 inhibitors for BPH/LUTS treatment and highlights th
47  importance of sex differences in the use of PDE5 inhibitors for treating heart disease and the criti
48                                   Men taking PDE5 inhibitors had a higher educational level and annua
49          Specifically, post-operative use of PDE5 inhibitors has a strong anti-cancer effect.
50                                    Recently, PDE5 inhibitors have been found to regulate smooth muscl
51                                              PDE5 inhibitors have the potential to be an adjuvant dru
52                         Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality o
53 uring this period, the prescription rate for PDE5 inhibitors in patients with IHD who were taking nit
54  especially after the therapeutic success of PDE5 inhibitors in the treatment of erectile dysfunction
55 e safety, efficacy and cost-effectiveness of PDE5 inhibitors in the treatment of LUTS secondary to BP
56 hich are both more potent and more selective PDE5 inhibitors in vitro than sildenafil.
57 dition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking water had a small effec
58                         Phosphodiesterase-5 (PDE5) inhibitors increase intracellular concentrations o
59                From 2000 to 2018, the use of PDE5 inhibitors increased 20-fold among Danish patients
60  tumor cells expressing mutant active K-RAS, PDE5 inhibitors interacted in a greater than additive fa
61 onal status, at clinically achievable doses, PDE5 inhibitors interacted in a greater than additive fa
62 her clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with clinically relevant che
63     Here we show that post-diagnostic use of PDE5 inhibitors is associated with a decreased risk of C
64 tes (nitrates) and phosphodiesterase type 5 (PDE5) inhibitors is contraindicated.
65 , NY), a selective phosphodiesterase type-5 (PDE5) inhibitor, is widely used to treat impotence by im
66 dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicated in the
67                         Vardenafil, a potent PDE5 inhibitor (K(i) = 0.2 nM), was the most potent PDE6
68                         Phosphodiesterase 5 (PDE5) inhibitors limit myocardial injury caused by stres
69           As well, chronic administration of PDE5 inhibitors may also help maintain the smooth muscle
70               Overall, the data suggest that PDE5 inhibitors may be a useful treatment for the cardio
71 tudies have provided promising evidence that PDE5 inhibitors may be an effective and well tolerated t
72 it appears from recent clinical studies that PDE5 inhibitors may increase the risk of malignant melan
73                           To clarify whether PDE5 inhibitors medication may affect the risk of cancer
74 pe 5 (PDE5) inhibitors plus another agent vs PDE5 inhibitor monotherapy.
75 or the combination of inhaled NO with either PDE5 inhibitor (n = 4 per group).
76 e in predicting long-term safety profiles of PDE5 inhibitors on cancer risk and highlight the potenti
77                     The present study tested PDE5 inhibitors on the cGMP-mediated modulation of K(+)
78 g critical insights into the side effects of PDE5 inhibitors on vision.
79 effects of tadalafil (Cialis), a long acting PDE5 inhibitor, on brain cGMP levels, neurogenesis, angi
80 t of Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, on nestin lineage neural stem cells and
81  a highly-specific type 5 phosphodiesterase (PDE5) inhibitor, on platelet-mediated cyclic coronary fl
82 nt and highly selective phosphodiesterase-5 (PDE5) inhibitor, on symptom-limited exercise time, time
83  aimed to assess the effects of tadalafil--a PDE5 inhibitor--on exercise capacity and quality of life
84  an increased risk of melanoma in men taking PDE5 inhibitors (OR, 1.21 [95% CI, 1.08-1.36]).
85 eclinical and experimental studies show that PDE5 inhibitors (PDE5is) exert protective effects in DN
86 e previously reported potent quinoline-based PDE5 inhibitors (PDE5Is) for the treatment of Alzheimer'
87 nclusion, the safety and efficacy profile of PDE5 inhibitor PF-00489791 supports further investigatio
88  the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinati
89 ation therapy with phosphodiesterase type 5 (PDE5) inhibitors plus another agent vs PDE5 inhibitor mo
90                                          The PDE5 inhibitors potentiated the antithrombotic propertie
91                        145,104 men with >/=1 PDE5 inhibitor prescription, and 560,933 unexposed match
92 ibitor and time-updated cumulative number of PDE5 inhibitor prescriptions were investigated as exposu
93                         Phosphodiesterase-5 (PDE5) inhibitors promote nitric oxide activity and enhan
94              Sildenafil (Viagra), a specific PDE5 inhibitor, promotes penile erection by blocking the
95 f tauopathies or Huntington's disease with a PDE5 inhibitor reduced the levels of the mutant huntingt
96 ata demonstrates that oral administration of PDE5 inhibitors selectively increases BTB permeability a
97 mising results in males, the efficacy of the PDE5 inhibitor sildenafil in female cardiac pathologies
98 d in vivo, but it has been proposed that the PDE5 inhibitor sildenafil is prothrombotic.
99       Number of filled prescriptions for the PDE5 inhibitors sildenafil and vardenafil or tadalafil.
100 udies indicate that the phosphodiesterase 5 (PDE5) inhibitor sildenafil is protective against hypertr
101       Surprisingly, the phosphodiesterase 5 (PDE5) inhibitor sildenafil was found to possess submicro
102                     To determine whether the PDE5-inhibitor sildenafil benefits human dystrophinopath
103 ly overcome by combing HBOC treatment with a PDE5 inhibitor (sildenafil).
104                                              PDE5 inhibitors (sildenafil, tadalafil, vardenafil, etc.
105 on of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improves skeletal and cardi
106                         Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil)
107 butyl-1-methyl-xanthine or the new selective PDE5 inhibitor, sildenafil, but it is inhibited by the P
108 ddition, treatment of mdx(5cv) mice with the PDE5 inhibitor, sildenafil, which was one of the six dru
109 5 in median inhibitory concentration for the PDE5 inhibitors, sildenafil, or zaprinast 3-isobutyl-1-m
110 In the present study, sildenafil, like other PDE5 inhibitors, stimulates cGMP binding to the alloster
111 t and selective pyrimidinyl pyrroloquinolone PDE5 inhibitors such as 2a for potential use in male ere
112 nic treatment of pulmonary hypertension with PDE5 inhibitors such as sildenafil.
113                                              PDE5 inhibitors such as Viagra block the activity of suP
114 n follow-on experiments the influence of the PDE5 inhibitor tadalafil on the development of doxorubic
115                             Similar to other PDE5 inhibitors, tadalafil should not be administered in
116 azoquinazolinone nucleus as a more selective PDE5 inhibitor template compared to the pyrazolopyrimidi
117 en identified as a more potent and selective PDE5 inhibitor than sildenafil (1).
118 otide field that culminated in the advent of PDE5 inhibitors that treat erectile dysfunction, such as
119 larities with PDE5, we utilized radiolabeled PDE5 inhibitors to probe the catalytic sites of PDE6.
120 e has been increasing interest in the use of PDE5 inhibitors to treat BPH/LUTS.
121 ate the ability of type 5 phosphodiesterase (PDE5) inhibitors to augment the antithrombotic effects o
122     This study compared adding sildenafil, a PDE5 inhibitor, to conventional treatment with the curre
123 continued investigation of combined HBOC and PDE5 inhibitor treatment in circumstances in which HBOC
124 t solar keratosis was associated with future PDE5 inhibitor use (odds ratio = 1.28, 95% CI 1.23-1.34,
125 ence of a small positive association between PDE5 inhibitor use and melanoma risk (HR = 1.14, 95% CI
126    We therefore aimed to investigate whether PDE5 inhibitor use is associated with an increased risk
127                                              PDE5 inhibitor use was also associated with an increased
128 onal studies found that phosphodiesterase 5 (PDE5) inhibitors use is linked to both increased and dec
129 gher sun exposure were more likely to become PDE5 inhibitor users.
130      The corona phase binds selectively to a PDE5 inhibitor, Vardenafil, as well as its molecular var
131                              The most potent PDE5 inhibitor was sildenafil.
132 ed to explore whether post-diagnostic use of PDE5 inhibitors was associated with a better prognosis a
133       In a Swedish cohort of men, the use of PDE5 inhibitors was associated with a modest but statist
134                The addition of a-blockers to PDE5 inhibitors was not associated with improvement in I
135 yl pyrroloquinolones as potent and selective PDE5 inhibitors was reported.
136                                              PDE5 inhibitors were significantly associated with melan
137  device therapy, dietary supplementation and PDE5 inhibitors which is described in detail.
138 ngs should not promote indiscriminate use of PDE5 inhibitors, which can also have harmful adverse eff
139  This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in
140 our data demonstrate that the combination of PDE5 inhibitors with standard of care chemotherapy agent
141 ction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h.
142 nafil, a type 5 phosphodiesterase isoenzyme (PDE5) inhibitor with a short half-life, increases brain
143                    Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity r
144  In addition, studies on animals reveal that PDE5 inhibitors work in concert with nitric oxide and/or
145 -polymerized bovine hemoglobin (HBOC) with a PDE5 inhibitor would counter the negative hemodynamic co
146 This activity was inhibited by the selective PDE5 inhibitors zaprinast and DMPPO.

 
Page Top